Stock Scorer

Envoy Medical, Inc. (COCH)

Envoy Medical, Inc. reported revenue of 51K USD for the quarter ending 30 June 2026, down 34.6% from 78K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 51K -34.6%
Gross Profit Q2 '26 · ending 30 June 2026 -227K —
Operating Income Q2 '26 · ending 30 June 2026 -5.6M —
Net Income Q2 '26 · ending 30 June 2026 -6M —
Cost of Revenue Q2 '26 · ending 30 June 2026 278K +18.8%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -5.5M —
Free Cash Flow Q4 '25 · ending 31 December 2025 -5.9M —
Shares Outstanding Q2 '26 · ending 30 June 2026 104M +387.8%
EPS Q2 '26 · ending 30 June 2026 -0.76 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 241K-22.3M-23.8M-18.4M
20242024-12-31 225K-19.3M-20.8M-18.9M
20232023-12-31 316K-18.4M-29.9M-17.2M
20222022-12-31 237K-8.7M-15.9M-9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3051K
Q1 '262026-03-3139K
Q4 '252025-12-3175K
Q3 '252025-09-3042K
Q2 '252025-06-3078K
Q1 '252025-03-3146K
Q4 '242024-12-3142K
Q3 '242024-09-3056K
Q2 '242024-06-3068K
Q1 '242024-03-3159K
Q4 '232023-12-3195K
Q3 '232023-09-3080K
Q2 '232023-06-3063K
Q1 '232023-03-3178K
Q4 '222022-12-3120K
Q3 '222022-09-3057K

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q2 '262026-06-30-227K
Q1 '262026-03-31-274K
Q4 '252025-12-31-136K
Q3 '252025-09-30-161K
Q2 '252025-06-30-156K
Q1 '252025-03-31-180K
Q4 '242024-12-31-115K
Q3 '242024-09-30-131K
Q2 '242024-06-30-177K
Q1 '242024-03-31-94K
Q4 '232023-12-31-139K
Q3 '232023-09-30-109K
Q2 '232023-06-30-99K
Q1 '232023-03-31-97K
Q4 '222022-12-31-131K
Q3 '222022-09-30-49K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-5.6M
Q1 '262026-03-31-6M
Q4 '252025-12-31-6.4M
Q3 '252025-09-30-5.7M
Q2 '252025-06-30-5.1M
Q1 '252025-03-31-5.1M
Q4 '242024-12-31-4.5M
Q3 '242024-09-30-5M
Q2 '242024-06-30-4.9M
Q1 '242024-03-31-4.9M
Q4 '232023-12-31-6.7M
Q3 '232023-09-30-3.4M
Q2 '232023-06-30-4.5M
Q1 '232023-03-31-3.8M
Q4 '222022-12-31-2.9M
Q3 '222022-09-30-1.8M
Q2 '222022-06-30-901.4K
Q1 '222022-03-31-1.5M
Q4 '212021-12-31-963.9K
Q3 '212021-09-30-3M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-6M
Q1 '262026-03-31-4.4M
Q4 '252025-12-31-6.6M
Q3 '252025-09-30-6.5M
Q2 '252025-06-30-5.7M
Q1 '252025-03-31-5M
Q4 '242024-12-31-4.6M
Q3 '242024-09-30-6M
Q2 '242024-06-30-3.9M
Q1 '242024-03-31-6.3M
Q4 '232023-12-31-4.9M
Q3 '232023-09-301.6M
Q2 '232023-06-30-13.3M
Q1 '232023-03-31-13.3M
Q4 '222022-12-312.3M
Q3 '222022-09-30-1.3M
Q2 '222022-06-30-1.2M
Q1 '222022-03-31-1.9M
Q4 '212021-12-31-4.7M
Q3 '212021-09-305.6M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30278K
Q1 '262026-03-31313K
Q4 '252025-12-31211K
Q3 '252025-09-30203K
Q2 '252025-06-30234K
Q1 '252025-03-31226K
Q4 '242024-12-31157K
Q3 '242024-09-30187K
Q2 '242024-06-30245K
Q1 '242024-03-31153K
Q4 '232023-12-31234K
Q3 '232023-09-30189K
Q2 '232023-06-30162K
Q1 '232023-03-31175K
Q4 '222022-12-31151K
Q3 '222022-09-30106K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-5.5M
Q1 '262026-03-31-6.1M
Q4 '252025-12-31-5.7M
Q3 '252025-09-30-4.3M
Q2 '252025-06-30-4.5M
Q1 '252025-03-31-3.7M
Q4 '242024-12-31-5.1M
Q3 '242024-09-30-2.6M
Q2 '242024-06-30-4.6M
Q1 '242024-03-31-5.6M
Q4 '232023-12-31-11.1M
Q3 '232023-09-301.1M
Q2 '232023-06-30-4M
Q1 '232023-03-31-3M
Q4 '222022-12-31-2.4M
Q3 '222022-09-30-5.3M
Q2 '222022-06-30-400.2K
Q1 '222022-03-31-772.7K
Q4 '212021-12-31-885.2K
Q3 '212021-09-30-701.4K

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-31-5.9M
Q3 '252025-09-30-4.3M
Q2 '252025-06-30-4.5M
Q1 '252025-03-31-3.7M
Q3 '242024-09-30-3.8M
Q1 '242024-03-31-5.7M
Q4 '232023-12-31-11.2M
Q3 '232023-09-301M
Q2 '232023-06-30-4M
Q1 '232023-03-31-3.1M
Q4 '222022-12-31-2.4M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30104M
Q1 '262026-03-3168.9M
Q3 '252025-09-3021.9M
Q2 '252025-06-3021.4M
Q1 '252025-03-3121.3M
Q3 '242024-09-3018.6M
Q2 '242024-06-3018.6M
Q1 '242024-03-3118.6M
Q3 '232023-09-3011.2M
Q2 '232023-06-3010.1M
Q1 '232023-03-3110.1M
Q3 '222022-09-3010.1M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.76
Q1 '262026-03-31-1.01
Q4 '252025-12-31-1.22
Q3 '252025-09-30-1.36
Q2 '252025-06-30-1.40
Q1 '252025-03-31-1.37
Q4 '242024-12-31-1.49
Q3 '242024-09-30-1.17
Q2 '242024-06-30-0.65
Q1 '242024-03-31-1.67
Q4 '232023-12-31-2.57
Q3 '232023-09-30-3.62
Q2 '232023-06-30-3.88